Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:disease
|
| gptkbp:affects |
neuromuscular junction
|
| gptkbp:associated_with |
small cell lung cancer
thymoma other malignancies |
| gptkbp:caused_by |
autoimmune response
|
| gptkbp:clinical_trial |
ongoing studies
autonomic dysfunction reflexes may be diminished proximal muscle weakness muscle strength may improve with repeated use |
| gptkbp:condition |
gptkb:myasthenia_gravis
|
| gptkbp:demographics |
more common in men
|
| gptkbp:diagnosis |
variable
electromyography blood tests for antibodies |
| gptkbp:first_described_by |
Eaton and Lambert
|
| https://www.w3.org/2000/01/rdf-schema#label |
lambert-eaton syndrome
|
| gptkbp:pathway |
antibodies against voltage-gated calcium channels
|
| gptkbp:premiered_on |
typically between 40 and 60
can occur in adults |
| gptkbp:prevalence |
rare
|
| gptkbp:research_areas |
neurology
oncology immunology |
| gptkbp:research_focus |
patient registries
treatment efficacy genetic predisposition environmental triggers quality of life assessments long-term outcomes biomarkers for diagnosis immunological markers understanding autoimmune mechanisms |
| gptkbp:symptoms |
fatigue
muscle weakness difficulty breathing difficulty swallowing dry mouth muscle cramps impaired vision improvement with exercise |
| gptkbp:treatment |
gptkb:mycophenolate_mofetil
gptkb:methotrexate gptkb:immunotherapy gptkb:cyclophosphamide gptkb:rituximab gptkb:Android gptkb:azathioprine physical therapy supportive care monoclonal antibodies symptomatic treatment plasma exchange immunosuppressive drugs acetylcholinesterase inhibitors IVIG |
| gptkbp:bfsParent |
gptkb:myasthenia_gravis
|
| gptkbp:bfsLayer |
5
|